U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07428369) titled 'A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)' on Feb. 03.
Brief Summary: This study is focused on participants with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for high dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT).
This study is evaluating a drug called linvoseltamab in combination with standard therapies for multiple myeloma called bortezomib (V) and lenalidomide (R). This combination is abbreviated as Linvo-VR.
The aim of this study is to compare how well Linvo-VR, with and without ASCT, treats myeloma to how well the ...